StockData
Penumbra Inc logo

Penumbra Inc (PEN) company profile

PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 15/3073% above fair value
$319.11−1.51 (-0.47%)

Close on Nov 17, 2026Market cap $12.58BP/E 80.4Yield –

About Penumbra

Surgical & Medical Instruments & Apparatus, SIC 3841

Penumbra develops and manufactures medical devices designed to address challenging vascular conditions throughout the body, operating as a single segment focused on thrombectomy, embolization, and access solutions. The company's thrombectomy portfolio includes computer-assisted vacuum aspiration systems, continuous aspiration mechanical catheters, and reperfusion devices used to treat ischemic stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia. In addition, it produces peripheral and neurovascular embolization devices, such as detachable coils and occlusion systems, alongside guide and intermediate access catheters and neurosurgical evacuation tools. Penumbra primarily sells these products directly to healthcare providers and hospital systems for use by specialist physicians, including interventional radiologists, neuroradiologists, vascular surgeons, neurosurgeons, and interventional cardiologists.

The enterprise maintains direct commercial sales forces across the United States, Canada, Australia, Singapore, and most European nations, supplemented by independent distributors in other international territories and a licensing partner in China. It conducts research, development, and manufacturing operations in Alameda and Roseville, California.

Summary of the business section of Penumbra's latest annual report, written by StockData.

Company profile

Company

Legal name
Penumbra Inc
Founded
2004
Headquarters
Alameda, CA
Address
One Penumbra Place 94502
Phone
(510) 995-2486
Employees
4,700, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Francisco, California

Stock & identifiers

Ticker
PEN
Exchange
NYSE
IPO date
Sep 18, 2015
Shares outstanding
39M, Oct 14, 2026
Public float
$9.70B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1321732
CUSIP
70975L107
ISIN
US70975L1070
FIGI
BBG001BP92V1
Share class FIGI
BBG001TRHPB0
LEI
549300RGE06P3ECANU72
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Adam ElsesserCEO, Director865,502
Maggie YuenChief Financial Officer20,563
Lambert ShiuChief Accounting Officer41,976
Johanna RobertsEVP, Gen. Counsel & Secretary69,416
Shruthi NarayanPresident31,283
Harpreet GrewalDirector8,719
Thomas WilderDirector5,095
Bridget O'RourkeDirector5,962
Arani BoseDirector259,609
Janet LeedsDirector6,639
Surbhi SarnaDirector4,293
Don W. KassingDirector9,909

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$851.62K$851.62K$2.85M$178$78
FY2024$630.47K$630.47K$1.84M$136$78
FY2023$601.62K$601.62K$622.62K$144$74
FY2022$601.62K$601.62K$1.78M$127$79
FY2021$497.79K$497.79K$1.31M$164$103
FY2020$219.03K$219.03K$475.77K$107$133

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
Adam Elsesser
Chief Executive Officer and former President
$850.00K–$1.62K$851.62K+35%
Maggie Yuen
Chief Financial Officer
$715.39K$1.71M$7.08K$2.43M+37%
Johanna Roberts
Executive Vice President, General Counsel and Secretary
$715.39K$1.71M$6.99K$2.43M+11%
Lambert Shiu
Chief Accounting Officer
$594.23K$1.58M$6.91K$2.18M+39%
Shruthi Narayan
President
$730.77K$3.64M$6.58K$4.38M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 18, 2015
Offer price
$30.00
Securities offered
4,000,000
Gross proceeds
$120.00M
Exchange
NYSE
First trading day
Sep 18, 2015
First-day close
$41.30+37.7%
Lock-up ends (est.)
Mar 16, 2016

“The initial public offering price of our common stock is $30.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 4,700 employees worldwide.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?